![Jacob Jay Gottlieb](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jacob Jay Gottlieb
Président chez
MEDICUS SCIENCES ACQUISITION CORP.
Profil
Jacob Jay Gottlieb is the founder of Visium Asset Management LP, founded in 2005, holding the title of Managing Partner & Chief Investment Officer from 2005 to 2018.
Dr. Gottlieb is the founder of Altium Capital Management LLC, founded in 2018, holding the title of Chief Executive Officer.
Dr. Gottlieb is the founder of Medicus Sciences Acquisition Corp., holding the title of Executive Chairman since 2020.
Former jobs include Analyst at Sanford C.
Bernstein & Co., Inc., Portfolio Manager at Merlin Biomed Group Hedge Funds, and Portfolio Manager at Balyasny Asset Management LP from 2001 to 2005.
Education includes an undergraduate degree from Brown University and a doctorate from New York University School of Medicine, conferred in 1997.
Postes actifs de Jacob Jay Gottlieb
| Sociétés | Poste | Début |
|---|---|---|
| MEDICUS SCIENCES ACQUISITION CORP. | Président | 26/11/2020 |
Altium Capital Management LP
 Altium Capital Management LP Investment ManagersFinance Altium Capital Managment focuses primarily on fundamental equity long/short strategies. Their investment universe is mostly concentrated in US-based small/micro-cap public companies, with significant near/medium-term catalysts, and those raising capital from institutional investors for the first time. The firm’s hedge fund invests in companies that provide progressive therapies. | Directeur Général | - |
Anciens postes connus de Jacob Jay Gottlieb
| Sociétés | Poste | Fin |
|---|---|---|
Visium Asset Management LP
 Visium Asset Management LP Investment ManagersFinance Visium Asset Management seeks to achieve consistent, positive absolute returns by investing in a variety of industry sectors and in a wide range of financial instruments. Such instruments include, but are not limited to, long or short positions in US or non-US publicly traded or privately issued or negotiated common stocks, preferred stocks, stock warrants and rights, corporate or sovereign debt, bonds, notes or other debentures or debt participations, commodities, partnership interests, interests in investment companies, convertible securities, swaps, options (purchased or written), swaptions, futures contracts and other derivative instruments. | Directeur Général | 14/05/2018 |
Balyasny Asset Management LP
 Balyasny Asset Management LP Investment ManagersFinance BAM aims to deliver consistent, uncorrelated absolute returns in all market environments. The firm manages multi-strategy investment funds which maintain a concentrated private equity portfolio. Their investment advisory services reflect a blend of strategies including fundamental long/short equity, macro & rates, systematic trading and event & credit investing. BAM’s long/short equity and equity trading strategies include (but are not limited to) investments and trading in the following market sectors: Energy, Health Care, Financials, Industrials, Information Technology, Consumer Staples and Consumer Discretionary. | Gestionnaire de Portefeuille-Actions | - |
Merlin Biomed Group Hedge Funds
 Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Gestionnaire de Portefeuille-Actions | - |
Sanford C. Bernstein & Co., Inc.
 Sanford C. Bernstein & Co., Inc. Investment ManagersFinance Profile Unavailable | Analyst-Equity | - |
Formation de Jacob Jay Gottlieb
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Sanford C. Bernstein & Co., Inc.
Sanford C. Bernstein & Co., Inc. Investment ManagersFinance Profile Unavailable | Finance |
Merlin Biomed Group Hedge Funds
Merlin Biomed Group Hedge Funds Investment ManagersFinance Merlin BioMed invests globally in public and private healthcare companies. The firm's hedge funds and long-term appreciation fund seek maximum capital appreciation from broad-based, global investment in small-, mid- and large-cap public and private companies in the areas of biotechnology, pharmaceuticals, medical devices, healthcare services and research products/services. This investment objective is characterized by an intensive, research-oriented, fundamental, bottom-up approach with a focus on new product innovation as a driver of sales and earnings growth. For private equity, the MerlinNexus objective is to realize long-term capital appreciation from investments in late-stage private companies, PIPEs (private investments in public entities) and select open market transactions. The fund is invested in all segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough products that meet clinical needs and can positively alter disease course and associated costs. | Finance |
Balyasny Asset Management LP
Balyasny Asset Management LP Investment ManagersFinance BAM aims to deliver consistent, uncorrelated absolute returns in all market environments. The firm manages multi-strategy investment funds which maintain a concentrated private equity portfolio. Their investment advisory services reflect a blend of strategies including fundamental long/short equity, macro & rates, systematic trading and event & credit investing. BAM’s long/short equity and equity trading strategies include (but are not limited to) investments and trading in the following market sectors: Energy, Health Care, Financials, Industrials, Information Technology, Consumer Staples and Consumer Discretionary. | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Visium Asset Management LP
Visium Asset Management LP Investment ManagersFinance Visium Asset Management seeks to achieve consistent, positive absolute returns by investing in a variety of industry sectors and in a wide range of financial instruments. Such instruments include, but are not limited to, long or short positions in US or non-US publicly traded or privately issued or negotiated common stocks, preferred stocks, stock warrants and rights, corporate or sovereign debt, bonds, notes or other debentures or debt participations, commodities, partnership interests, interests in investment companies, convertible securities, swaps, options (purchased or written), swaptions, futures contracts and other derivative instruments. | Finance |
New York University School of Medicine
 New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altium Capital Management LP
Altium Capital Management LP Investment ManagersFinance Altium Capital Managment focuses primarily on fundamental equity long/short strategies. Their investment universe is mostly concentrated in US-based small/micro-cap public companies, with significant near/medium-term catalysts, and those raising capital from institutional investors for the first time. The firm’s hedge fund invests in companies that provide progressive therapies. | Finance |
Medicus Sciences Acquisition Corp.
 Medicus Sciences Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
